Patents Assigned to LigoCyte Pharmaceutical
-
Patent number: 8409590Abstract: Anthrax antigens are provided that find use as immunogens and vaccines.Type: GrantFiled: February 11, 2005Date of Patent: April 2, 2013Assignee: Ligocyte Pharmaceuticals, Inc.Inventor: Susan Wimer-Mackin
-
Publication number: 20130052216Abstract: The present invention provides particle-forming chimeric proteins comprising a Calicivirus capsid protein and one or more heterologous antigen sequences. In particular, the present invention discloses engineered Calicivirus capsid protein sequences containing heterologous epitopes fused at internal locations such that the modified capsid proteins retain the ability to form virus-like particles when expressed in host cells. Virus-like particles comprising the chimeric proteins and vaccine formulations are also described.Type: ApplicationFiled: January 21, 2011Publication date: February 28, 2013Applicant: LIGOCYTE PHARMACEUTICALS, INC.Inventors: Bryan Steadman, Ross Taylor
-
Publication number: 20130028933Abstract: Methods of stabilizing solutions with enveloped vims-based virus-like particles containing an influenza antigen and such stabilized solutions are described.Type: ApplicationFiled: December 28, 2010Publication date: January 31, 2013Applicant: LigoCyte Pharmaceuticals, Inc.Inventors: Joel R. Haynes, Bryan Steadman
-
Publication number: 20120156243Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.Type: ApplicationFiled: June 16, 2010Publication date: June 21, 2012Applicant: LigoCyte PharmaceuticalInventors: Charles RICHARDSON, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
-
Publication number: 20120093855Abstract: The present invention relates to the field of isolation of enveloped virus-based virus-like particles (VLPs) free of infectious agents. In preferred examples, the field includes methods of inactivation of infectious agents that do not adversely affect the immunogenicity of the enveloped virus-based VLPs. In certain embodiments, the enveloped virus-based VLPs are produced in insect cell based expression systems.Type: ApplicationFiled: November 18, 2009Publication date: April 19, 2012Applicant: LIGOCYTE PHARMACEUTICALS, INC.Inventor: Joel R. Haynes
-
Publication number: 20110195113Abstract: The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed.Type: ApplicationFiled: February 8, 2011Publication date: August 11, 2011Applicant: LigoCyte Pharmaceuticals, Inc.Inventors: Charles RICHARDSON, Robert F. Bargatze, Joel Haynes, Bryan Steadman
-
Patent number: 7955603Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.Type: GrantFiled: September 28, 2007Date of Patent: June 7, 2011Assignee: Ligocyte Pharmaceuticals, Inc.Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
-
Publication number: 20100266636Abstract: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.Type: ApplicationFiled: April 22, 2010Publication date: October 21, 2010Applicant: Ligocyte Pharmaceuticals, Inc.Inventors: Charles RICHARDSON, Thomas S. Vedvick, Thomas R. Foubert
-
Publication number: 20100074915Abstract: Chimeric Influenza virus-like particles including gag polypeptides are described. Virus-like particles are generated with a gag polypeptide, a neuraminidase polypeptide and optionally a hemagglutinin polypeptide. Preferred methods of generation include expression in insect cells.Type: ApplicationFiled: July 27, 2007Publication date: March 25, 2010Applicant: LigoCyte Pharmaceuticals, Inc.Inventor: Joel R. Haynes
-
Publication number: 20100047266Abstract: Chimeric virus-like particles including gag polypeptides are described. Virus-like particles are generated with a gag polypeptide and lipid raft-associated polypeptide linked to an antigen that is not naturally associated with a lipid raft. Preferred methods of generation include expression in insect cells.Type: ApplicationFiled: July 27, 2007Publication date: February 25, 2010Applicant: LigoCyte Pharmaceuticals, Inc.Inventor: Joel R. Haynes
-
Publication number: 20040247611Abstract: This application relates to assays for identifying pathogen-ligand interactions under shear conditions, and to pathogen adhesin molecules and peptides identified thereby. Such adhesin molecules and peptides may be used as vaccines or therapeutic agents in the prevention and treatment of microbial infections.Type: ApplicationFiled: February 19, 2004Publication date: December 9, 2004Applicants: Montana State University, Ligocyte Pharmaceuticals, Inc.Inventors: Robert Bargatze, John Jutila, Jim Cutler, Yongmoon Han, Barry Pyle